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Abstract 
We developed a novel process, “controlled crystallization during freeze-drying” to 
produce drug nanocrystals of poorly water soluble drugs. This process involves freeze-drying 
at a relatively high temperature of a drug and a matrix material from a mixture of tertiary 
butyl alcohol and water, resulting in drug nanocrystals incorporated in a matrix. The aim of 
this study was to elucidate the mechanisms that determine the size of the drug crystals. 
Fenofibrate was used as a model lipophilic drug. To monitor the crystallization during freeze-
drying, a Raman probe was placed just above the sample in the freeze-dryer. These in-line 
Raman spectroscopy measurements clearly revealed when the different components 
crystallized during freeze-drying. The solvents crystallized only during the freezing step, 
while the solutes only crystallized after the temperature was increased, but before drying 
started. Although the solutes crystallized only after the freezing step, both the freezing rate 
and the shelf temperature were critical parameters that determined the final crystal size. At a 
higher freezing rate, smaller interstitial spaces containing the freeze-concentrated fraction 
were formed, resulting in smaller drug crystals (based on dissolution data). On the other hand, 
when the solutes crystallized at a lower shelf temperature, the degree of supersaturation is 
higher, resulting in a higher nucleation rate and consequently more and therefore smaller 
crystals. In conclusion, for the model drug fenofibrate, a high freezing rate and a relatively 
low crystallization temperature resulted in the smallest crystals and therefore the highest 
dissolution rate. 
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Introduction 
Many newly developed drugs are categorized as class II drugs according to the 
Biopharmaceutics Classification System (1). These drugs have a low solubility in water, but 
once dissolved, they are easily absorbed over the gastro-intestinal membrane (2-3). For many 
of these drugs, the dissolution rate is the rate-limiting step for absorption. Therefore the 
bioavailability can be improved by increasing the dissolution rate (4). One strategy for 
increasing the dissolution rate is the application of drug nanocrystals (5-8). The dissolution 
rate of nanocrystals is increased by their increased surface area (Noyes-Whitney equation) (9), 
the decreased thickness of the diffusion boundary layer (10), and the increased saturation 
concentration around the small particles (Kelvin’s law) (11).  
Current methods to prepare drug nanocrystals can be divided into top-down and 
bottom-up methods. Most currently used top-down methods are high-pressure 
homogenization (12) and wet-ball milling (13). Disadvantages of these methods include, the 
use of surfactants, the difficulty of achieving a uniform size distribution, low yields, and 
possible contamination from grinding media (14-16). For currently used bottom-up methods, 
disadvantages include the use of toxic solvents and the difficulty of adequately controlling the 
particle size (16-17).  
To overcome these disadvantages, we developed a novel bottom-up process to produce 
drug nanocrystals: controlled crystallization during freeze-drying (CCDF) (18). Briefly, this 
method consisted of the following steps. Firstly, two solutions are prepared: one is a solution 
of the poorly water-soluble drug in tertiary butyl alcohol (TBA) and the other is a solution of 
a matrix-material in water. These solutions are mixed, frozen, and then freeze-dried. Freeze-
drying is performed at a relatively high temperature to allow both the drug and the matrix to 
crystallize. By using this process, nanocrystalline dispersions with improved dissolution 
behavior were obtained.  
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When we developed this process, we found that the size of the nanocrystals was 
affected by the process conditions, such as the freezing rate. However, it was not clear during 
which stage of the process the solutes crystallized and how the freezing rate caused its effect 
on the crystal size. Since the mixture is thermodynamically unstable, the drug and the matrix 
could crystallize 1) during freezing, 2) after freezing at a temperature above the temperature 
of the maximally freeze concentrated fraction (Tg’), or 3) during drying. Knowledge on when 
and how crystallization occurs can help to elucidate the mechanisms through which 
parameters such as freezing rate affect the final size of the crystals. Crystallization processes 
can be monitored with Raman spectroscopy.  The effects of the process conditions on the drug 
particle size could be elucidated if the crystallization of both the solvents and the solutes 
could be monitored during the freeze-drying process.  
The aim of the study was to elucidate the mechanisms that determine the size of the 
drug crystals formed during freeze-drying. Thereto, in-line Raman spectroscopy was used as 
process analytical tool. Since Raman spectroscopy is a fast, non-invasive technique, it offers 
the opportunity to monitor physical changes of the formulation during freeze-drying. One of 
the advantages of Raman spectroscopy is that Raman spectra show sharp peaks by which 
individual components generally do not overlap each other. This makes it relatively easy to 
determine which component crystallizes at which stage during the process (19).  
In this study, a Raman probe was placed immediately above the sample in the freeze-
drier (as described by De Beer et al. (20)). By using this in-line method, the crystallization of 
the four components (a model drug, matrix, TBA, and water) during the process could be 
monitored. The different stages during the CCDF-process (freezing, increase in temperature, 
and drying) were separated from each other and prolonged to ensure that the complete phase 
changes during each stage were measured. In addition, two process conditions, the freezing 
rate and the temperature of the freeze-dryer shelf, were varied. Monitoring the crystallization 
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process yields insight into the moment and length of the crystallization of the different 
components, while varying the process conditions reveals which factors influence the model 
drug crystal size and therefore the dissolution rate. Fenofibrate and mannitol were used as the 
model drug and the matrix material, respectively.  
 
Materials and Methods 
Materials 
Fenofibrate and TBA were obtained from Sigma-Aldrich Chemie B.V. Zwijndrecht, 
The Netherlands. Mannitol was purchased from VWR international (Fontenay sous Bois, 
France).  
 
Methods 
Preparation of the crystalline dispersions 
Crystallized dispersions were prepared similarly to the method described previously 
(18). Briefly, the drug, fenofibrate, was dissolved in TBA (25 mg/ml) and the matrix material, 
mannitol, in water (31 mg/ml). The solutions were heated to approximately 60 °C and 2.4 ml 
of the aqueous solution was mixed with 1.6 ml of the TBA solution. After mixing, the vials 
were frozen. Two freezing rates were used: immediately freezing the vials on a precooled (-50 
°C) freeze-dryer shelf (cooling rate of the sample approximately 2.5 ºC/min); and freezing at 
1 °C/min by placing the vial on the shelf at 20 °C and cooling the shelf to -50 °C at a rate of 1 
°C/min (cooling rate of the sample approximately 0.8 ºC/min). In both cases, the temperature 
of -50 ºC was maintained for two hours. The temperature of the shelf was then increased to 
either -25 °C or -15 °C in 30 minutes and this temperature was maintained for another seven 
hours. Next, sublimation of the solvents was initiated by decreasing the pressure to 0.8-1.0 
mbar in 20 minutes and the samples were dried for 30 h (see Table I). The temperature of the 
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shelf was then gradually (two hours) raised to room temperature. Finally, the freeze-dryer 
(Amsco-Finn Aqua GT4 freeze-dryer) was emptied and the samples, having a drug load of 
35% w/w, were stored in a vacuum desiccator over silica gel for at least one day before 
further processing.  
 
In-line Raman spectroscopy 
A non-contact probe coupled to a RamanRxn1 spectrometer (Kaiser Optical Systems, 
Ann Arbor, Michigan, USA) via a glass fiber optic cable, was placed immediately above a 
vial inside the freeze-dryer. The spectrometer was equipped with an air-cooled CCD detector 
(back-illuminated deep depletion design). The laser wavelength was the 785 nm line from a 
785 Invictus NIR diode laser. Spectra were collected every minute during freeze-drying and 
the exposure time was 30 seconds. All spectra were recorded at a resolution of 4 cm-1 using a 
laser power of 400 mW. The HoloREACT reaction analysis and profiling software package, 
the Matlab Software package (version 6.5), and the Grams/AI-PLSplusIQ software package 
(version 7.02) were used for data-collection, –transfer, and –analysis. Spectra were 
preprocessed by baseline correction (Pearson’s  method).   
 
Differential scanning calorimetry (DSC) 
The degree of crystallinity (defined as the ratio between the heat of fusion of the drug 
or carrier in the solid dispersion and the heat of fusion of the drug or carrier as received 
multiplied by the fraction drug or carrier in the mixture) of fenofibrate and mannitol in the 
crystallized dispersions was determined by DSC. Hermetically closed aluminum pans were 
filled with 2-8 mg of the sample and heated at 2 °C/min, from -50 to 200 °C in the scanning 
calorimeter (Q2000, TA Instruments, Ghent, Belgium).  
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X-ray powder diffraction (XRPD) 
XRPD was used to determine the crystallinity and identify the polymorphic forms of 
both solutes. Therefore a CuKα radiation with a wavelength of 1.5405 Å at 40 kV and 40 mA 
from an X'Pert PRO MPD diffractometer (PANalytical, Almelo, The Netherlands) was used. 
The sample powders were placed on a zero-background silicon holder (diameter, 32 mm; 
thickness, 2 mm) and scanned from 4–60° 2θ with a step size of 0.008° and a time per step of 
35 s. 
 
Tabletting 
The obtained powders were compressed to 9-mm tablets of 100 mg on a ESH 
compaction apparatus (Hydro Mooi, Appingedam, The Netherlands). The compaction rate 
was 5 kN/s to a maximum compaction load of 5 kN. The tablets were stored in a vacuum 
desiccator over silica gel at room temperature for at least one day before further processing. 
 
Dissolution 
The dissolution rate of fenofibrate from these tablets was tested in a USP dissolution 
apparatus II, Rowa Techniek. Dissolution was performed in 1 L of a 0.5% w/v sodium 
dodecyl sulphate solution at 37 °C; the paddle speed was 100 rpm. The concentration of 
fenofibrate was measured spectrophotometrically (UV-VIS spectrophotometer UV-1601, 
Shimadzu) at a wavelength of 290 nm. 
 
Results 
Physicochemical characterization of the dispersions 
The physical properties of the obtained freeze-dried product were determined by both 
DSC and XRPD. The DSC-thermograms of all four dispersions showed melting peaks 
corresponding to crystalline fenofibrate and crystalline mannitol. Mannitol exists as three 
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anhydrous polymorphs whose melting points differ only slightly (166.5, 166, and 155 °C for 
the α-, β-, and δ-polymorphs, respectively (21)). Therefore DSC is not the most suitable 
method to identify which polymorph has been formed. The XRPD patterns showed that all 
samples contained only the δ-polymorph (Fig. 1). Although the pure mannitol as received did 
not consist of δ-mannitol, DSC can be used to determine the degree of crystallinity of 
mannitol since the melting enthalpies of α-, β-, and δ-mannitol are also similar (21). 
Fenofibrate and mannitol in all four dispersions were highly crystalline and had a similar 
degree of crystallinity (96-102 % for fenofibrate and 92-95% for mannitol; Table II).  
 
In-line Raman spectroscopy 
Each crystalline component had a characteristic peak that did not overlap with 
characteristic peaks of any of the other components (Fig. 2). The characteristic peak used for 
fenofibrate was at 1580-1610 cm-1, for mannitol at 865-895 cm-1, for TBA at 725-763 cm-1, 
and for water at 208-226 cm-1 (22-24). Since these peaks can be clearly distinguished from 
each other, it is possible to use in-line Raman spectroscopy to monitor the crystallization of 
the individual components. To determine when crystallization of fenofibrate, δ-mannitol, and 
water started and ended, the peak intensity of each individual characteristic peak was 
determined. An increase in peak intensity indicates the start of crystallization. The peak 
intensity of the TBA peak can not be used for the determination of the start and end of the 
TBA crystallization, since liquid TBA already shows a peak with a high intensity. Therefore 
the width of the TBA peak was used to determine the crystallization of TBA. A narrowing of 
the peak indicates the start of the crystallization of TBA (25). Furthermore, it should be 
mentioned that Raman spectroscopy only allows to measure the surface of the sample.  
The intensity of the water peak increased and the width of the TBA peak decreased 
during the freezing stage of process 1 (Fig. 3), corresponding to the crystallization of the 
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solvents. The intensity of the fenofibrate peak decreased slightly due to the decrease in 
temperature and the the peak of crystalline mannitol was not detected during this stage of the 
CCDF-process. Thus only the solvents and not the solutes crystallized during the freezing 
stage. After approximately 80 minutes, the intensity of the solvent peaks did not change 
anymore, indicating that almost all solvent had crystallized. At this point during the CCDF-
process, the system consisted of crystalline water (ice), crystalline TBA, and a vitrified 
freeze-concentrated solution of fenofibrate and mannitol in a mixture of water and TBA.  
After the temperature was increased to -25 ºC, the intensity of the peaks corresponding 
to both fenofibrate and mannitol increased. Indicating that the solutes crystallized at this 
stage. Since the intensities did not change any further after approximately 460 and 480 
minutes for fenofibrate and mannitol, respectively (Table III), which was well before the 
vacuum was applied (after 640 minutes), these data show that fenofibrate and mannitol 
crystallized completely before the drying step started. After 650 minutes the width of the TBA 
peak increased and the intensity of the water peak decreased, indicating that sublimation 
started immediately after the pressure was decreased. Due to the sublimation of the solvents, 
the concentration of the solutes, and therefore the intensities of the solute peaks, increased. 
After 1144 and 980 minutes the peaks of TBA and water, respectively, disappeared. Since 
only the surface of the sample can be measured by Raman spectroscopy, this indicates that the 
top of the sample was dried in approximately 8.5 hours. To end with a completely dry 
crystalline dispersion, the total drying time used was 30 hours.  
The solutes and solvents of the other three processes crystallized at the same stages of 
the freeze-drying process as found for process 1 (Table III; note that step 2 of process 3 and 4 
start 70 minutes earlier than step 2 of process 1 and 2, due to the different freezing rate). The 
solvent crystallized upon cooling, while crystallization of the solutes was not observed at this 
stage. The solutes crystallized after the temperature had been increased to -25 ºC (processes 1 
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and 3) or -15 ºC (processes 2 and 4). Even if the mixture was cooled at a rate of at least 1 
ºC/min, the solutes did not crystallize during freezing, but only after the temperature was 
increased. Since the intensity of the solute peaks reached a constant value before the vacuum 
was applied, the solutes indeed crystallized only during the time between freezing and drying.  
 
Dissolution 
As expected from earlier studies (18, 26), the dissolution rate of samples that were 
made by rapid freezing (vials placed on a pre-cooled freeze-dryer shelf) was higher than the 
dissolution rate of samples that were frozen more slowly (at 1 °C/min) (see Fig. 4). 
Furthermore, a relatively low shelf temperature during the crystallization stage (-25 ºC) 
resulted in faster dissolution than a relatively high shelf temperature (-15 ºC). Between the 
samples that were crystallized at a relatively low temperature, the effect of the freezing rate 
on the dissolution behavior is negligible, indicating that crystallization at a lower temperature 
could diminish the effect of the freezing rate. Since all samples had a similar degree of 
crystallinity and consisted of the same polymorphic forms, differences in dissolution rate can 
be attributed to differences in crystal size (18, 26). Thus, both the rate of freezing and the 
temperature at which crystallization occurs influence the final particle size. Based on the 
dissolution data, we conclude that a higher freezing rate and a lower temperature at which the 
solutes crystallized, resulted in smaller drug crystals.  
 
Discussion 
In this study, we clearly elucidated the mechanism of crystallization during the CCDF-
process. The in-line Raman spectroscopy measurements showed that the solvents and the 
solutes crystallized at different steps during the CCDF-process. During the freezing step, the 
solvents crystallize. Due to the crystallization of the solvents, the remaining solution becomes 
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more concentrated. Since the remaining solution (containing fenofibrate, mannitol, TBA, and 
water) is thermodynamically unstable, the solutes can start to crystallize as well. However, if 
the freezing occurs rapidly, and if the system is cooled to a temperature well below the Tg’, 
the mobility is strongly reduced and a rigid glass is formed. Due to the strongly reduced 
mobility neither the solvents nor the solutes can crystallize in the freeze-concentrated fraction. 
The in-line Raman data show that the solutes did not crystallize at the freezing stage of the 
CCDF-process. Thus, the freezing rate (even at 1 ºC/min) is apparently fast enough to prevent 
crystallization of the solutes during freezing and the reached temperature of -50 ºC is well 
below the Tg’.  
After step 2, when the temperature was increased to either -25 ºC or -15 ºC, the solutes 
crystallized and the crystallization was finished before the next step, drying, was started. The 
Tg’ of the solutes could not be properly measured in this complex system by DSC (data not 
shown), but since the solutes crystallized at these temperatures, the temperature of the system 
was apparently above the Tg’. At temperatures below the Tg’, the freeze-concentrated fraction 
is glassy and the solutes can not crystallize.  
Although the solutes crystallized solely during the step after the freezing step, not only 
the crystallization temperature, but also the freezing rate determined the particle size of the 
powder. Therefore we conclude that two phenomena play a role in the formation and growth 
of the crystals during CCDF.  
The first process variable that determines the final crystal size was the freezing rate. A 
higher freezing rate resulted in smaller crystals. This effect was already shown in an earlier 
study, in which we also speculated about different mechanisms that could determine the drug 
crystal size (18). Since we have shown in this study that both the drug and the matrix 
crystallized after freezing, we conclude that the size of the solvent crystals determines the 
final solute crystal size. A higher freezing rate results in smaller solvent crystals (27) and 
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consequently smaller interstitial spaces, containing the freeze-concentrated fraction, between 
the solvent crystals. Since the solutes crystallized in the freeze-concentrated fraction, the size 
of the interstitial spaces limits the final size of the solute crystals. Thus, a high freezing rate 
results in smaller solvent crystals and therefore smaller interstitial spaces and consequently 
smaller solute crystals.  
The second process variable that determines the crystal size is the shelf temperature. 
We found that a lower shelf temperature during crystallization (-25 ºC vs. -15 ºC) resulted in 
smaller crystals. At a lower shelf temperature, the degree of supersaturation is higher, 
resulting in a higher nucleation rate (28). Since the formation of new nuclei and crystal 
growth are two competing processes (29), a higher nucleation rate results in more nuclei and 
consequently in smaller crystals. Thus, although the size of the interstitial spaces (controlled 
by the freezing rate) determines the maximum particle size, the crystal size is also determined 
by the balance between the formation of new nuclei and crystal growth (controlled by the 
shelf temperature).  
 
Conclusion 
In this study we revealed during which stages of the CCDF-process the solvents as 
well as the solutes crystallized. Based on this, we identified the critical steps for crystal 
formation for the model drug fenofibrate during freeze-drying. CCDF consists of three 
successive steps: freezing, increasing the temperature, and drying. The in-line Raman 
measurements showed that the first two steps, the freezing step and the crystallization step are 
critical steps that determine the final size of the fenofibrate crystals. When the mixture was 
frozen more rapidly, the interstitial spaces between the solvent crystals are smaller and 
because the size of the solute crystals is limited by the size of the interstitial spaces, smaller 
fenofibrate crystals are formed. When the solutes crystallize at a lower shelf temperature, the 
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degree of supersaturation in the freeze-concentrated fraction is higher. A higher degree of 
supersaturation (as caused by lower crystallization temperatures) results in a higher nucleation 
rate and consequently more and therefore smaller fenofibrate crystals are formed. The 
combination of a high freezing rate and a relative low crystallization temperature results in the 
smallest fenofibrate crystals and consequently a higher dissolution rate. Furthermore these 
results show that the fenofibrate crystal size can be controlled by choosing the appropriate 
freezing rate and shelf temperature. Further studies are necessary to prove whether the critical 
steps as defined in this study and the mechanism of crystal formation are generally applicable 
to other lipophilic drugs.  
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TABLES 
 
Table 1. Description of the process and its variables to crystallize and freeze-dry the 
water/TBA mixtures.  
Step Temperature ( ºC) Length of step (h) Pressure (mBar) 
1. Freezing Variable 1 1000 
 -50 2 1000 
2. Ramping to Tc* Variable 2 0.5 1000 
3. Crystallization Variable 2 7 1000 
4. Drying Variable 2 30 0.8-1.0 
5. Ramping to Tend 20 2 0.8-1.0 
 20 1 0.8-1.0 
6. Emptying 20 - 1000 
    
Process Variable 1: freezing rate Variable 2: Tc* 
1. (Slow; -25 ºC) From 20 to -50 ºC at 1 ºC/min -25 ºC 
2. (Slow; -15 ºC) From 20 to -50 ºC at 1 ºC/min -15 ºC 
3. (Fast; -25 ºC) Vial on pre-cooled shelf (-50 ºC); -25 ºC 
4. (Fast; -15 ºC) Vial on pre-cooled shelf (-50 ºC); -15 ºC 
*
 Tc: Crystallization temperature 
Table 2. Degree of crystallinity of both drug and matrix (mean  ± standard deviation; n=3).  
 Degree of crystallinity 
Process Fenofibrate Mannitol 
1. (Slow; -25 ºC) 102.3 ± 0.8 91.9 ± 0.2 
2. (Slow; -15 ºC) 99.5 ± 0.6 92.5 ± 0.6 
3. (Fast; -25 ºC) 96.4 ± 2.2 95.1 ± 1.2 
4. (Fast; -15 ºC) 100.2 ± 1.2 91.5 ± 2.1 
 
 
Table 3. Summary of the average time at which the crystallization of each individual 
component starts and ends.  
 Crystallization times (min) 
 Process 1 Process 2 Process 3 Process 4 
 Start End Start End Start End Start End 
Fenofibrate 291 461 273 353 243 439 207 307 
Mannitol 237 480 231 379 222 475 199 314 
TBA 59 75 44 67 15 30 14 25 
Water 71 80 63 68 19 33 21 26 
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FIGURE LEGENDS 
 
Fig. 1.  
A) X-ray diffraction patterns of fenofibrate as received, α-, β- and δ-mannitol and B) the 
controlled crystallized dispersions containing 35% w/w fenofibrate in mannitol (patterns of 
the mannitol polymorphs were taken from the ICDD-library).  
 
Fig. 2.  
Raman spectrum of the sample during freeze-drying it according to process 1 after 500 
minutes. The peaks used to determine the intensities of the individual components are 
encircled. 
 
Fig. 3.  
The intensities of fenofibrate (1580-1610 cm-1), mannitol (865-895 cm-1), and water (208-226 
cm-1) peaks and the peak width of TBA (725-763 cm-1) during the first 1000 minutes of 
process 1. During this process the freeze-drier shelf was cooled during the first 70 minutes 
from 20 ºC to -50 ºC, then the temperature was kept constant at -50 ºC for 120 minutes, then 
the temperature of the freeze-drier shelf was increased to -25 ºC in 30 minutes and kept 
constant for 420 minutes. Finally, the pressure was decreased to 0.8-1.0 mBar to dry the 
samples. 
 
Fig. 4.  
Dissolution profiles of tablets composed of a physical mixture (■) and controlled crystallized 
dispersions of 35% w/w fenofibrate in mannitol. Controlled crystallized dispersions were 
prepared by slow freezing (closed symbols) or fast freezing (open symbols) and a low (-25 
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ºC) crystallization temperature (circles) or a high (-15 ºC) crystallization temperature 
(triangles). Process 1 corresponds to (●), process 2 corresponds to (▲), process 3 corresponds 
to (○), and process 4 corresponds to (∆) (n=3-6; mean ± standard deviation).  
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FIGURES 
 
Figure 1. 
 
A) X-ray diffraction patterns of fenofibrate as received, α-, β- and δ-mannitol (patterns of the 
mannitol polymorphs were taken from the ICDD-library) and B) the controlled crystallized 
dispersions containing 35% w/w fenofibrate in mannitol. 
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Figure 2. 
 
 
Raman spectrum of the sample during freeze-drying it according to process 1 after 500 
minutes. The peaks used to determine the intensities of the individual components are 
encircled.  
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Figure 3.  
 
 
The intensities of fenofibrate (1580-1610 cm-1), mannitol (865-895 cm-1), and water (208-226 
cm-1) peaks and the peak width of TBA (725-763 cm-1) during the first 1000 minutes of 
process 1. During this process the freeze-drier shelf was cooled during the first 70 minutes 
from 20 ºC to -50 ºC, then the temperature was kept constant at -50 ºC for 120 minutes, then 
the temperature of the freeze-drier shelf was increased to -25 ºC in 30 minutes and kept 
constant for 420 minutes. Finally, the pressure was decreased to 0.8-1.0 mBar to dry the 
samples. 
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Figure 4.  
 
 
Dissolution profiles of tablets composed of a physical mixture (■) and controlled crystallized 
dispersions of 35% w/w fenofibrate in mannitol. Controlled crystallized dispersions were 
prepared by slow freezing (closed symbols) or fast freezing (open symbols) and a low (-25 
ºC) crystallization temperature (circles) or a high (-15 ºC) crystallization temperature 
(triangles). Process 1 corresponds to (●), process 2 corresponds to (▲), process 3 corresponds 
to (○), and process 4 corresponds to (∆) (n=3-6; mean ± standard deviation).  
  
 
 
